Skip to main content
XTL Biopharmaceuticals Ltd. logo

XTL Biopharmaceuticals Ltd. — Investor Relations & Filings

Ticker · XTLB ISIN · IL0010854979 LEI · 529900NDDXEAPTUTXP41 TA Manufacturing
Open in API
Filings indexed 1,223 across all filing types
Latest filing 2007-03-15 Annual Report
Country IL Israel
Listing TA XTLB

About XTL Biopharmaceuticals Ltd.

https://www.xtlbio.com

XTL Biopharmaceuticals Ltd. is a clinical-stage biopharmaceutical company focused on the acquisition and development of pharmaceutical products to address unmet clinical needs. The company's primary therapeutic area of interest is autoimmune diseases. Its development pipeline has included proprietary drug candidates for conditions such as Systemic Lupus Erythematosus (SLE).

Recent filings

Filing Released Lang Actions
Report of Periodic or Interim Report
Annual Report Classification · 95% confidence The document is a detailed announcement of financial results for the year ended December 31, 2006, including comprehensive financial statements such as balance sheets, statements of operations, changes in shareholders' equity, and cash flows. It contains actual financial data and analysis for the full fiscal year, not just highlights or a brief summary. The presence of detailed financial tables and management commentary on financial performance confirms this is a full annual financial report. The document is not a brief earnings release, regulatory filing, or announcement of report publication, but the full report itself. Therefore, the appropriate classification is Annual Report (10-K equivalent for a foreign company). FY 2006
2007-03-15 Hebrew (modern)
Report of Periodic or Interim Report
Report Publication Announcement Classification · 98% confidence The document is a formal notification dated 15/03/2007, referencing the 'Report of Periodic or Interim Report' under Israeli regulations. Crucially, it states: 'Attached hereto is a report on *Financial Results For The Year Ended 31 December, 2006*'. This structure—a short announcement stating that the full financial results document is attached (or linked, implied by the filename reference)—fits the definition of a Report Publication Announcement (RPA) rather than the full Annual Report (10-K) or Interim Report (IR) itself. The content is an announcement about the release of the annual financial results.
2007-03-15 English
Investor Presentation 2007
Investor Presentation Classification · 85% confidence The document is a Form 6-K filing by a foreign private issuer, XTL Biopharmaceuticals Ltd., submitted to the SEC. It announces the company's CEO's upcoming presentation at an investor conference, including details about the presentation topic, date, and webcast information. The document does not contain financial statements, detailed financial analysis, or comprehensive management discussion. It is primarily an announcement of an event (investor presentation) rather than the presentation materials themselves or a detailed report. The document length is 3794 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, the most appropriate classification is Investor Presentation (IP), as it relates to a presentation for investors focusing on company strategy and market position, even though the actual presentation content is not included, the announcement is about the presentation event.
2007-03-05 English
Other Report or Announcement
Investor Presentation Classification · 70% confidence The document is a press release announcing that the CEO of XTL Biopharmaceuticals will present at an investor conference focused on pain management. It includes details about the presentation topic, timing, and webcast information. There is no financial data, regulatory filing, or detailed report content. The document is a company announcement about an upcoming investor presentation event, not the presentation itself or a financial report. Therefore, the most appropriate classification is Investor Presentation (IP). However, since the actual presentation content is not included, but only the announcement of the presentation, it fits best as an Investor Presentation announcement. Given the options, the closest match is Investor Presentation (IP) with moderate confidence.
2007-03-05 Hebrew (modern)
Other Report or Announcement
Report Publication Announcement Classification · 98% confidence The document is a short regulatory filing (1604 characters) from XTL BIOPHARMACEUTICALS LTD, dated 05/03/2007. It explicitly states under 'Other Report or Announcement' that it is attaching a report titled '*Presentation at Oppenheimer’s Conference*' with the filename 'OPCOMarch62007_isa.pdf'. According to Rule 2 (The 'MENU VS MEAL' Rule), a short document announcing the publication of a presentation or report should be classified as a Report Publication Announcement (RPA). This is not the full presentation itself, but the notification of its release.
2007-03-05 English
Regulatory Filings 2007
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed by a foreign private issuer, XTL Biopharmaceuticals Ltd., with the SEC. It announces that the CEO will present at an upcoming investor conference and provides details about the presentation and company overview. The document is short (3654 characters) and primarily serves as an announcement of an event and company information rather than containing financial statements or detailed financial analysis. It does not contain quarterly or annual financial results, nor does it include management discussion or detailed financial data. Therefore, it is not an Interim Report, Annual Report, or Earnings Release. It is also not a regulatory certification or insider transaction report. The content fits best as a Regulatory Filing (RNS) because it is a general regulatory announcement that does not fit into more specific categories.
2007-02-08 English

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.